Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been assigned a consensus rating of "Buy" from the six analysts that are covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $7.80.

TRVI has been the subject of several recent analyst reports. EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics to a "strong-buy" rating in a research report on Monday, August 19th. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, May 8th. Rodman & Renshaw assumed coverage on Trevi Therapeutics in a research note on Thursday, June 13th. They set a "buy" rating and a $7.00 target price on the stock. Raymond James started coverage on Trevi Therapeutics in a research report on Friday. They set an "outperform" rating and a $9.00 price target for the company. Finally, HC Wainwright assumed coverage on Trevi Therapeutics in a report on Friday. They set a "buy" rating and a $6.00 price target on the stock.

Trevi Therapeutics Price Performance

Shares of TRVI stock traded up $0.25 on Friday, hitting $3.16. 289,419 shares of the stock traded hands, compared to its average volume of 236,473. The company has a market capitalization of $229.38 million, a PE ratio of -9.29 and a beta of 1.00. The company's fifty day moving average is $2.84 and its 200 day moving average is $2.84. Trevi Therapeutics has a 1-year low of $0.97 and a 1-year high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). During the same period in the prior year, the company posted ($0.07) EPS. As a group, equities research analysts expect that Trevi Therapeutics will post -0.46 EPS for the current year.

Insiders Place Their Bets

In other news, insider Thomas Sciascia sold 18,660 shares of Trevi Therapeutics stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the transaction, the insider now directly owns 220,315 shares in the company, valued at approximately $608,069.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold 23,315 shares of company stock worth $65,123 over the last ninety days. Company insiders own 24.37% of the company's stock.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. American Century Companies Inc. raised its holdings in shares of Trevi Therapeutics by 17.1% in the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company's stock worth $161,000 after purchasing an additional 7,902 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Trevi Therapeutics by 87.6% in the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company's stock worth $73,000 after buying an additional 11,450 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in Trevi Therapeutics in the first quarter worth approximately $47,000. Hsbc Holdings PLC bought a new position in shares of Trevi Therapeutics in the second quarter valued at $61,000. Finally, Rhumbline Advisers lifted its position in shares of Trevi Therapeutics by 44.8% during the 2nd quarter. Rhumbline Advisers now owns 75,218 shares of the company's stock valued at $224,000 after acquiring an additional 23,263 shares during the last quarter. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.